The modest response to EZH2 inhibition was also confirmed using other EZH2 catalytic inhibitors (valemetostat (24), PF-06821497 (25), and GSK126 (26)) two of which are in clinical trials for prostate cancer (NCT04388852, NCT03460977) (SFig 1A-C). The gene discussed is EZH2; the disease is prostate carcinoma.